Clodronic acid
Based on 4 publication(s) in Google Scholar
Clodronic acid (Clodronate) is an orally active bisphosphonate. Clodronic acid inhibits osteoclast-mediated bone resorption. Clodronic acid reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid is effective in the maintenance or improvement of bone mineral density. Clodronic acid can be used for the research of multiple myeloma and postmenopausal osteoporosis.
For research use only. We do not sell to patients.
- Purity: 99.41%
- CAS No.: 10596-23-3
- Formula: CH4Cl2O6P2
- Molecular Weight:244.89
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Blood Cancer Compound Library
HY-L079
-
Rare Diseases Drug Library
HY-L102
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Macrophage Related Compound Library
HY-L174
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Clodronic acid
More
Biological Activity
Clodronic acid induces rapid apoptosis in osteoclasts by preventing translocation of ADP into mitochondria after being internalised via resorption. Consequently, ATP production is inhibited, leading to induction of apoptosis by means of release of cytochrome C into the cytoplasm[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Lewis rats, aged 7 weeks[3]
-
Dosage:6.25, 12.5, and 25 mg/kg
-
Administration:P.o.; daily for 28 days
-
Result:Hindpaw swelling was significantly smaller than in adjuvant-arthritis (AA)-control at 25 mg/kg on days 21 and 28 (87 and 88% of AA-control, respectively) and at 12.5 mg/kg on day 28.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 10596-23-3
-
Appearance Solid-Liquid Mixture
-
Molecular Weight 244.89
-
Formula CH4Cl2O6P2
-
Color Colorless to light yellow
-
SMILES
ClC(P(O)(O)=O)(Cl)P(O)(O)=O
-
Synonyms
Clodronate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nat Neurosci
Spatiotemporally selective astrocytic ATP dynamics encode injury information sensed by microglia following brain injury in mice. [Abstract]2024 Aug;27(8):1522-1533. PMID: 38862791 -
J Adv Res
Dual regulation of phaseol on osteoclast formation and osteoblast differentiation by targeting TAK1 kinase for osteoporosis treatment. [Abstract]2024 Dec 9:S2090-1232(24)00565-4. PMID: 39662728 -
Phytomedicine
Glycyrol alleviates osteoporosis through dual modulation on osteoclastogenesis and osteogenesis by targeting Syk signaling pathway. [Abstract]2025 Mar:138:156429. PMID: 39939034 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618
Solvent & Solubility
DMSO : 125 mg/mL (510.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (416 KB)
- English - EN (416 KB)
- Français - FR (416 KB)
- Deutsch - DE (416 KB)
- Norwegian - NO (416 KB)
- Español - ES (416 KB)
- Swedish - SV (416 KB)
- Italian - IT (416 KB)
- Portuguese - PT (416 KB)
-
Handling Instructions (2659 KB)
References
[1]. Morgan GJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376(9757):1989-1999. [Content Brief]
[2]. Tanakol R, et al. Clodronic acid in the treatment of postmenopausal osteoporosis. Clin Drug Investig. 2007;27(6):419-433. [Content Brief]
[3]. Itoh F, et al. Effects of clodronate and alendronate on local and systemic changes in bone metabolism in rats with adjuvant arthritis. Inflammation. 2004 Feb;28(1):15-21. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0835 mL | 20.4173 mL | 40.8347 mL | 102.0867 mL |
| 5 mM | 0.8167 mL | 4.0835 mL | 8.1669 mL | 20.4173 mL | |
| 10 mM | 0.4083 mL | 2.0417 mL | 4.0835 mL | 10.2087 mL | |
| 15 mM | 0.2722 mL | 1.3612 mL | 2.7223 mL | 6.8058 mL | |
| 20 mM | 0.2042 mL | 1.0209 mL | 2.0417 mL | 5.1043 mL | |
| 25 mM | 0.1633 mL | 0.8167 mL | 1.6334 mL | 4.0835 mL | |
| 30 mM | 0.1361 mL | 0.6806 mL | 1.3612 mL | 3.4029 mL | |
| 40 mM | 0.1021 mL | 0.5104 mL | 1.0209 mL | 2.5522 mL | |
| 50 mM | 0.0817 mL | 0.4083 mL | 0.8167 mL | 2.0417 mL | |
| 60 mM | 0.0681 mL | 0.3403 mL | 0.6806 mL | 1.7014 mL | |
| 80 mM | 0.0510 mL | 0.2552 mL | 0.5104 mL | 1.2761 mL | |
| 100 mM | 0.0408 mL | 0.2042 mL | 0.4083 mL | 1.0209 mL |
Powered by Bioz